← LCTX
LCTX— Lineage Cell Therapeutics, Inc.
MaterialsBiological Products, (No Diagnostic Substances)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Total revenues | $947K-29.9% | $1.4M-0.5% | $1.4M+1.6% | $1.3M-69.2% | $4.3M+137.7% | $1.8M-48.1% | $3.5M |
| Cost of royalties | $146K-56.3% | $334K | — | — | — | — | — |
| Research and development | $17.7M+42.2% | $12.5M-20.6% | $15.7M+12.3% | $14.0M-58.8% | $33.9M+175.3% | $12.3M-31.4% | $17.9M |
| General and administrative | $18.5M+1.6% | $18.2M+5.0% | $17.3M-23.1% | $22.5M+23.6% | $18.2M+17.0% | $15.6M-35.2% | $24.0M |
| Loss on impairment of intangible asset (Note 6 and Note 13) | $14.8M | $0 | — | — | — | — | — |
| Total operating expenses | $51.2M+65.2% | $31.0M-8.0% | $33.7M-7.7% | $36.5M-30.0% | $52.1M+86.9% | $27.9M-33.6% | $42.0M |
| Loss from operations | -$36.6M-70.5% | -$21.5M+13.2% | -$24.7M-9.8% | -$22.5M+54.2% | -$49.2M-86.1% | -$26.4M+32.0% | -$38.9M |
| Interest income, net | $1.7M-1.4% | $1.7M+5.3% | $1.6M+96.5% | $829K+41350.0% | $2K-99.8% | $1.0M-38.3% | $1.7M |
| Loss on marketable equity securities, net | -$8K+0.0% | -$8K+95.5% | -$176K+92.0% | -$2.2M | — | — | — |
| Change in fair value of warrant liability | -$35.7M-1778.9% | $2.1M | $0-100.0% | $225K | — | — | — |
| Foreign currency transaction gain (loss), net | $2.1M+898.5% | -$269K+50.6% | -$544K | — | — | — | — |
| Other income (expense), net | -$132K+80.3% | -$670K-223.6% | $542K+125.2% | -$2.2M-244.8% | $1.5M-48.4% | $2.9M+13.7% | $2.5M |
| Total other income (expenses) | -$32.0M-1205.9% | $2.9M+99.6% | $1.5M+144.1% | -$3.3M-155.4% | $5.9M+31.4% | $4.5M-77.0% | $19.6M |
| LOSS BEFORE INCOME TAXES | -$68.6M-269.4% | -$18.6M+20.2% | -$23.3M+9.8% | -$25.8M+40.3% | -$43.3M-97.4% | -$21.9M-14.0% | -$19.2M |
| Income tax benefit | $5.3M | $0-100.0% | $1.8M+433.3% | -$541K | — | — | $7.4M |
| NET LOSS | -$63.4M-241.0% | -$18.6M+13.5% | -$21.5M+18.5% | -$26.4M+39.1% | -$43.3M-109.2% | -$20.7M-74.9% | -$11.8M |
| Net (income) loss attributable to noncontrolling interest | -$166K-514.8% | -$27K-285.7% | -$7K-108.7% | $80K-68.1% | $251K+597.2% | $36K-69.5% | $118K |
| NET LOSS ATTRIBUTABLE TO LINEAGE | -$63.5M-241.4% | -$18.6M+13.4% | -$21.5M+18.2% | -$26.3M+38.9% | -$43.0M-108.3% | -$20.6M-76.4% | -$11.7M |
| Net loss per common share attributable to Lineage basic | -$280-211.1% | -$90+25.0% | -$120+20.0% | -$150+42.3% | -$260 | — | — |
| Net loss per common share attributable to Lineage diluted | -$280-211.1% | -$90+25.0% | -$120+20.0% | -$150 | — | — | — |
| Weighted-average common shares used to compute net loss per common share, basic | $230.1M+14.9% | $200.2M+15.9% | $172.7M+1.7% | $169.8M+3.2% | $164.5M | — | — |
| Weighted-average common shares used to compute net loss per common share, diluted | $230.1M+14.9% | $200.2M+15.9% | $172.7M+1.7% | $169.8M | — | — | — |
| Collaboration Revenues [Member] | |||||||
| Royalties, License and Other Revenues [Member] | |||||||
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.